ERBB2 and cancer: Moreover, both pertuzumab and trastuzumab facilitate antibody-dependent cell-mediated cytotoxicity (ADCC), with preferential exertion on HER2-overexpressing cancer cells in vitro compared to those lacking HER2 overexpression (Hudis, 2007; Greenblatt and Khaddour, 2024).